No Data
No Data
Medicenna to Provide Clinical Update on the MDNA11 ABILITY-1 Trial at the Upcoming American Association for Cancer Research Annual Meeting
Medicenna Reports MDNA11's Compelling Anti-Cancer Activity Is Associated With Significant Expansion of 'Stem-Like' Cancer Fighting Immune Cells at the Inaugural AACR-Immuno-Oncology Conference and Provides ABILITY-1 Study Update
Medicenna Therapeutics up 12% Following Third-Quarter Results
Medicenna Reports Third Quarter Fiscal 2025 Financial and Operational Results and Provides Anticipated Milestones
Medicenna Therapeutics Corp: INTERIM FINANCIAL STATEMENTSREPORT LETTER FROM FOREIGN ISSUER
Medicenna Therapeutics to Participate in Two Healthcare Investor Conferences in February 2025